Updated Credit Information for ACI-Pittsburgh:
Physician Continuing Medical education Credit Designation
The Postgraduate Institute for Medicine designates this live activity for a maximum of 3.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Medical education Credit Designation
The maximum number of hours awarded for this Continuing Nursing Education activity is 3.0 contact hours. Designated for 2.9 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Pharmacist Continuing education Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 3.00 contact hour(s) (0.3 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Numbers:
JA4008162-9999-18-468-L01-P (S1, S2; Application, 2.5 hours)
JA4008162-9999-18-469-L04-P (S3; Knowledge; 0.5 hours)
American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Program Purpose
Specifically designed by the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, nurse practitioners, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) programs are introductory, CE- and MOC-accredited programs. Presented by leading and local authorities in tumor immunology and cancer immunotherapy, these 4 hour long programs will facilitate understanding of:
- The rationale for common approaches to immunotherapy
- The appropriate clinical management of common side effects of immunotherapy agents
- Implementing appropriate cancer immunotherapy treatments for melanoma, lung, genitourinary, head and neck, and/or hematologic cancers in clinical practice
- Overcoming operational and financial barriers to integrating cancer immunotherapy into their practice setting
- Appropriate implementation of cancer care counsel in the clinical setting
Attendees will also have an opportunity for connecting with regional experts in the immunotherapy field at the live event, through four quarterly webinars, and indefinitely through a dedicated online community forum. These connections will serve as ongoing resources while clinical oncologists and other healthcare providers incorporate immunotherapy into practice.
For more information, including program objectives, click here.
View the SITC Meeting Code of Conduct.
The 2018-2019 Advances in Cancer Immunotherapy™ series is brought to you in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association.
The 2018–2019 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc.